Orthobiologic Treatment for Knee Osteoarthritis

Launched by UNIVERSITY HOSPITAL OF NORTH NORWAY · Mar 17, 2025

Keywords

ClinConnect Summary

Patients will be randomized into one of four treatment groups and then be followed up at 6 weeks, 12 weeks, 6 months, 1 year and 2 years after intervention. They will fill out scores and be clinically evaluated, as well as radiologically examined at inclusion and at the final check up (x-ray and MRI).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Symptomatic osteoarthritis in the knee grade I-III using the Kellgren-Lawrance Grading Scale
• • Age 40-70 years
• • Minimum VAS 3
• • No use of NSAIDs or steroids the last 14 days
• • No injections of hyaluronic acid the last three months
• • Varus/valgus deformity \<5 degrees as evaluated on x-ray imaging
• Exclusion Criteria:
• • Pregnant or breastfeeding women
• • Cancer
• • Other etiologies of knee pain (refered pain, pain from the back, dislocated meniscus on MRI, osteoarthritis grade IV using the Kellgren-Lawrance Grading Scale)
• • Previous knee surgery on the affected knee
• • Secondary osteoarthritis in the knee
• • Previous infection in the knee
• • Other diseases (rheumatoid arthritis, diabetes, systemic diseases or corticosteroid-demaning disease)
• • Patients with a high risk of deep vein thrombosis
• • Patients who cannot cooperate/are low compliance (psychiatric disease) or has contraindications for MRI